Parallel trade is now very much a part of the European pharmaceutical
landscape. And as such you cannot avoid at some point being affected by it.
It is essential, therefore, that you learn how to deal with it so you can begin
implementing counter measures to minimise the risk it poses to your
profitability.

This report tells you everything you need to know about parallel trade and
provides expert advice on what you can do to tackle it.

This report provides:

- a complete and independent overview of parallel trade, which explains the complex economic, legal and regulatory aspects involved, so you can assess the potential impact it may have on your profitability
- a clear and comprehensive guide to the legal and regulatory issues that surround parallel trade, enabling you to get to grips with this complex area more quickly
- key market profiles, detailing the regional variations that provide the perfect environment for parallel trade to thrive so you can understand,
country to country, how this affects the industry
- profiles of leading parallel importers - so you can build a thorough understanding of the companies involved and their activities
- expert guidance on how to respond strategically to parallel trade - discover how you can combat parallel trade and cut the risk to your bottom line
- an exploration of the future prospects for parallel trade - so you can prepare for the future and be ready to pre-empt the parallel traders' next steps.

About the author:

From 2001-2005, Donald Macarthur was Secretary General of the
European Association of Euro-Pharmaceutical Companies (EAEPC),
the pan-European grouping of national associations and individual
firms involved in parallel trading of medicines with membership from
16 EEA countries.

During the preceding 16 years he was an independent consultant
and analytical writer on global pharmaceutical business issues. He
has produced 40+ reports and his consultancy clients have included
the European Federation of Pharmaceutical Industries and Associations
(he was the very first consultant ever used by EFPIA), PhRMA, the
European grouping of national full-line pharmaceutical wholesaling
associations (GIRP), government agencies, and several major
multinational manufacturers and financial firms.

He spent 16 years in development, regulatory affairs and medical
department functions in the pharmaceutical industry in the UK
(Fisons, 1969-72; Parke-Davis, 1972-75; Roche, 1976-78;
Serono, 1978-82; Lundbeck 1982-84) and is A Member of the Royal
Pharmaceutical Society and Visiting Professor in European Pharmacy
Practice & Policy at the School of Pharmacy (University of London).
He is listed in Marquis' Who's Who in the World.